Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 4Colorectal Neoplasms 2Turcot syndrome 1Sarcoma 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1COVID-19 1Advanced Pancreatic Cancer 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 93Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 51Doxorubicin 50atezolizumab 48trametinib 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms × IMM-101 × Clear all
NCT04442048 2025-12-30

COV-IMMUNO

Canadian Cancer Trials Group

Phase 3 Completed
195 enrolled

COVID-19, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡